Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8560245 | 0.88 | ALDH1A1 (0.43) | ALDH1A1KDM4EUSP2ALOX15MEN1 | |
| SCHEMBL5557277 | 0.87 | ALDH1A1 (0.46) | ALDH1A1KDM4EUSP2ALOX15MEN1 | |
| SCHEMBL8481805 | 0.86 | ALDH1A1 (0.48) | ALDH1A1KDM4EUSP2ALOX15MEN1 | |
| SCHEMBL5551517 | 0.85 | ALDH1A1 (0.45) | ALDH1A1KDM4EUSP2ALOX15MEN1 | |
| SCHEMBL8559141 | 0.84 | ALDH1A1 (0.52) | ALDH1A1KDM4EUSP2ALOX15MEN1 | |
| SCHEMBL5551332 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4EUSP2ALOX15MEN1 | |
| SCHEMBL5551323 | 0.82 | PIK3CD (0.33) | ALOX15LMNA | |
| SCHEMBL5551312 | 0.82 | KDM4E (0.43) | ALDH1A1KDM4EUSP2ALOX15MEN1 | |
| SCHEMBL5555297 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KDM4EUSP2ALOX15MEN1 | |
| SCHEMBL5555359 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4EUSP2ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208139-B2 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | SCHERING AG (DE) | 2007-04-24 | — | — | US | disclosed |
| US-20050118105-A1 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-06-02 | — | — | US | disclosed |
| US-6855309-B2 | For use in diagnostics and therapy | SCHERING, AG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20030232017-A1 | For use in diagnostics and therapy | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6576222-B2 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-10 | — | — | US | disclosed |
| EP-0662972-B1 | 3-,8-SUBSTITUTED DEUTEROPORPHYRINE DERIVATIVES, PHARMACEUTICALS CONTAINING THEM AND METHODS OF PRODUCING THEM | DIAGNOSTIKFORSCHUNG INST (DE) | 2002-10-30 | — | — | EP | disclosed |
| US-6451837-B1 | Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors | BASKYS ANDRIUS (US) | 2002-09-17 | — | — | US | disclosed |
| US-20020068037-A1 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | SCHERING AG (DE) | 2002-06-06 | — | — | US | disclosed |
| US-6299859-B1 | ADMINISTERING CONTRAST AGENT COMPRISING CASCADE POLYMER COMPLEX AND NUCLEAR MAGNETIC RESONANCE IMAGING TISSUES FOR DIFFERENTIATING ISCHEMIC AND/OR INFRACTED TISSUE FROM NORMAL TISSUES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-10-09 | — | — | US | disclosed |
| US-6193950-B1 | FOR DIAGNOSIS AND THERAPY | SCHERING AG (DE) | 2001-02-27 | — | — | US | disclosed |
| EP-0485045-B1 | Mono-N-substituted 1,4,7,10-Tetraazacyclododecan-derivatives, process for their preparation and pharmaceutical agent containing them | SCHERING AG (DE) | 1998-12-30 | — | — | EP | disclosed |
| US-5849259-A | 3-,8-substituted deuteroporphyrin derivatives, pharmaceutical agents containing the latter and process for their production | INSTITUT FUR DIAGNOSTIKFORSCHUNG GMBH (DE) | 1998-12-15 | — | — | US | disclosed |
| EP-0512661-B1 | Macrocyclic polymer-complexing, their complexes, method for their production and pharmaceutical agents containing them | SCHERING AG (DE) | 1998-01-14 | — | — | EP | disclosed |
| US-5650136-A | Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-22 | — | — | US | disclosed |
| EP-0662972-A1 | 3-,8-SUBSTITUTED DEUTEROPORPHYRINE DERIVATIVES, PHARMACEUTICALS CONTAINING THEM AND METHODS OF PRODUCING THEM | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN (DE) | 1995-07-19 | — | — | EP | disclosed |
| US-5364614-A | Cascade polymer bound chelating compounds, their chelates and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | disclosed |
| WO-1994007894-A1 | 3-,8-SUBSTITUTED DEUTEROPORPHYRINE DERIVATIVES, PHARMACEUTICALS CONTAINING THEM AND METHODS OF PRODUCING THEM | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GMBH (DE) | 1994-04-14 | — | — | WO | disclosed |
| US-5277895-A | Nuclear magnetic resonance | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-11 | — | — | US | disclosed |
| EP-0512661-A1 | Macrocyclic polymer-complexing, their complexes, method for their production and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0485045-A2 | Mono-N-substituted 1,4,7,10-Tetraazacyclododecan-derivatives, process for their preparation and pharmaceutical agent containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068037-A1 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | CAD, APOB, SLC7A1 | ALDH1A1 4841/4885KDM4E 4688/4885USP2 4755/4885 |
| US-20030232017-A1 | For use in diagnostics and therapy | TFPI, BCAT2, OAT | ALDH1A1 3976/4885KDM4E 4762/4885USP2 4539/4885 |
| US-20050118105-A1 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | FABP7, SLC1A3, SLC43A1 | ALDH1A1 4833/4885KDM4E 4731/4885USP2 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.